Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data

Résumé détaillé

Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease. The post Amgen, In A Buy Zone, Unveils Highly…

After several high-profile setbacks among its competitors, Amgen (AMGN) unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease. In Sjogren's disease, the immune system mistakenly attacks the body's moisture-producing glands. This can lead to dry eyes and mouth, joint and muscle pain, and organ dysfunction. Patients were given infusions of Amgen's…

Début de l'article, extrait de Investor's Business Daily. Pour lire la suite, ouvrez l'article chez le média.